The degradation of NPs can be either receptor- mediated (NPR-C) or enzyme-mediated [5,6,7,8,9,10] and is recognized as a therapeutic target in both hypertension and HF [12,16]. The gene discussed is NPR3; the disease is hydrops fetalis.